A Study of Cabergoline for the Treatment of Cocaine Dependence - 1
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00033111|
Recruitment Status : Completed
First Posted : April 8, 2002
Last Update Posted : January 12, 2017
|Condition or disease||Intervention/treatment||Phase|
|Cocaine-Related Disorders Substance-Related Disorders||Drug: Cabergoline Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||140 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Phase 2, Double-Blind, Placebo Controlled Trial of Cabergoline for the Treatment of Cocaine Dependence|
|Study Start Date :||June 2001|
|Actual Study Completion Date :||April 2004|
Active Comparator: Cabergoline
Subjects received one tablet of 0.5 mg of cabergoline tablet per week for 12 weeks.
Other Name: Dostinex
Placebo Comparator: Placebo
Subjects received one tablet of 0.5 mg of cabergoline matched placebo tablet per week for 12 weeks.
sugar pill manufactured to mimic cabergoline 05mg tablet
- To assess the efficacy of cabergoline in reducing cocaine use in subjects with cocaine dependence [ Time Frame: Week 12 ]Success in the reduction of cocaine use was determined by comparing cocaine non-use days (self-report confirmed or disproved by urine BE level at each study visit) expressed as the weekly mean proportion of non-use days to the total number of non-missing study days that week.
- Reduction in cocaine use [ Time Frame: 12 weeks ]Measured by the weekly mean proportion of non-use days according to the subject's self report without regard to BE levels
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00033111
|United States, California|
|Torrance, California, United States, 90502|
|United States, South Carolina|
|Medical University of South Carolina|
|Charleston, South Carolina, United States, 29425|
|Principal Investigator:||Steve Shoptaw, Ph.D.||Friends Research Institute, Inc.|